Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04460326 · ClinicalTrials.gov registry record · Phase 3
Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus
A Phase 3 study, sponsored by Boston Medical Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 137
- Enrollment target
NCT04460326 is a Phase 3 study that has completed, run by Boston Medical Center. The registered enrollment target is 137 participants.
The verdict
NCT04460326, a Phase 3 study, has completed, sponsored by Boston Medical Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 137 participants
- Enrollment target
Study Summary
Hyperglycemia affects 30-40% of hospitalized patients. Despite the fact that basal/bolus insulin therapy has been demonstrated to improve glycemic control and clinical outcomes in patients, achieving good glucose control remains a challenge. This study examines the effects of Fiasp (a faster acting insulin) on blood sugars after meals compared to another type of insulin known as Novolog. The study will be performed in patients with type 2 diabetes admitted to the hospital, who are not in the intensive care unit, and who are being seen by the inpatient diabetes consult team. Eligible participants will be treated with Fiasp or Novolog injected multiple times a day before meals and at bedtime, in addition to a once daily injection of insulin glargine as basal insulin. Which type of meal time insulin (Fiasp vs Novolog) the subject gets is decided by chance, like the flip of a coin. Insulin doses will be started and titrated based on a protocol. All the subjects will wear a blinded continuous glucose monitoring (CGM)) sensor placed in their arm which they will wear for 72 hours during the study. The glucose values from the CGM, collected during the time it is worn, will be downloaded and compared to assess the response to the two different types of insulins - Fiasp and Novolog. The goal is to determine if Fiasp works as well as or better than Novolog in controlling blood sugars, particularly after meals, in the subjects of the study.
Interventions
- DRUG Insulin glargine
- OTHER Standard carbohydrate diet
- DRUG NovoLog
- DRUG Insulin Fiasp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2020-12-07 |
| Est. Completion | 2023-05-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04460326
The ClinicalTrials.gov registry entry for NCT04460326 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Medical Center, which has 253 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Insulin glargine is the first listed.
NCT04460326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04460326 about?
NCT04460326 is a clinical study titled "Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus". Hyperglycemia affects 30-40% of hospitalized patients. Despite the fact that basal/bolus insulin therapy has been demonstrated to improve glycemic control and clinical outcomes in patients, achieving good glucose control remains a challenge. This study examines the effects of Fiasp (a faster acting...
What is the current status of trial NCT04460326?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 137 participants. The study started on 2020-12-07. Estimated completion is 2023-05-27.
What interventions are being tested in trial NCT04460326?
The interventions under investigation include: Insulin glargine (DRUG), Standard carbohydrate diet (OTHER), NovoLog (DRUG), Insulin Fiasp (DRUG).
Who is sponsoring clinical trial NCT04460326?
This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.